An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma

Background:Malignant pleural mesothelioma (MPM) is an aggressive tumour originating in the thoracic mesothelium. Prognosis remains poor with 9- to 12-month median survival, and new targets for treatments are desperately needed.Methods:Utilising an RNA interference (RNAi)-based screen of 40 genes overexpressed in tumours, including genes involved in the control of cell cycle, DNA replication and repair, we investigated potential therapeutic targets for MPM. Following in vitro characterisation of the effects of target silencing on MPM cells, candidates were assessed in tumour samples from 154 patients.Results:Gene knockdown in MPM cell lines identified growth inhibition following knockdown of NDC80, CDK1 and PLK1. Target knockdown induced cell-cycle arrest and increased apoptosis. Using small-molecule inhibitors specific for these three proteins also led to growth inhibition of MPM cell lines, and Roscovitine (inhibitor of CDK1) sensitised cells to cisplatin. Protein expression was also measured in tumour samples, with markedly variable levels of CDK1 and PLK1 noted. PLK1 expression in over 10% of cells correlated significantly with a poor prognosis.Conclusion:These results suggest that RNAi-based screening has utility in identifying new targets for MPM, and that inhibition of NDC80, CDK1 and PLK1 may hold promise for treatment of this disease.

[1]  D. Henderson,et al.  Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. , 2013, Clinical lung cancer.

[2]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[3]  E. Nigg.  Polo-like kinases: positive regulators of cell division from start to finish. , 1998, Current opinion in cell biology.

[4]  M. Abaza,et al.  Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. , 2008, World journal of gastroenterology.

[5]  C. Parker,et al.  An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC) , 2008 .

[6]  Kyungeun Kim,et al.  Overexpressions of Cyclin B1, cdc2, p16 and p53 in Human Breast Cancer: The Clinicopathologic Correlations and Prognostic Implications , 2011, Yonsei medical journal.

[7]  Y. Shukla,et al.  Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells. , 2010, Biochemical pharmacology.

[8]  H. Ackermann,et al.  Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer , 1997, Oncogene.

[9]  S. Lundgren,et al.  pleural mesothelioma : Genome-wide expression patterns reflecting eneral resistance mechanisms and a proposal of novel targets luf , 2009 .

[10]  M. Monden,et al.  Expression and Prognostic Role of Cyclin-Dependent Kinase 1 (cdc2) in Hepatocellular Carcinoma , 2000, Oncology.

[11]  Birgit Gaschler-Markefski,et al.  The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  M. Zheng,et al.  Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells , 2012, Medical science monitor : international medical journal of experimental and clinical research.

[13]  F. Rödel,et al.  Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol , 2008, BMC Cancer.

[14]  R. Hofheinz,et al.  An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors , 2010, Clinical Cancer Research.

[15]  Eri Kawata,et al.  RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers , 2011, Journal of Clinical Bioinformatics.

[16]  D. Henderson,et al.  Validation of tissue microarray technology in malignant pleural mesothelioma , 2011, Pathology.

[17]  E. Raymond,et al.  Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. , 2010, European journal of cancer.

[18]  R. Kaufmann,et al.  Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease , 2002, Journal of cutaneous pathology.

[19]  Sorin Draghici,et al.  Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma , 2004, Clinical Cancer Research.

[20]  R. Kaiser,et al.  Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. , 2012, Current oncology.

[21]  E. Dı́az-Rodrı́guez,et al.  Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo , 2008, Proceedings of the National Academy of Sciences.

[22]  A. Olshen,et al.  Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. , 2006, Cancer research.

[23]  A. Thompson,et al.  Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome , 2012, Breast Cancer Research.

[24]  A. Thompson,et al.  Seliciclib (CYC202, R‐roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model , 2009, International journal of cancer.

[25]  Bing Feng,et al.  MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. , 2012, Cancer letters.

[26]  Sunil Singhal,et al.  Gene expression profiling of malignant mesothelioma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  B. Lanphear,et al.  Latent period for malignant mesothelioma of occupational origin. , 1992, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[28]  K. Strebhardt,et al.  Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. , 2006, Cancer research.

[29]  E. Duhig,et al.  Phenotypes and Karyotypes of Human Malignant Mesothelioma Cell Lines , 2013, PloS one.

[30]  G. Kroemer,et al.  Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe , 2002, Cell Death and Differentiation.

[31]  P. Ellis,et al.  A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. , 2013, Clinical lung cancer.

[32]  Michael D. Taylor,et al.  Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells , 2012, BMC Cancer.

[33]  S. Dunn,et al.  Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells , 2012, Breast Cancer Research.

[34]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Elevated expression of Rad18 regulates melanoma cell proliferation , 2012, Pigment cell & melanoma research.

[36]  H. Lane,et al.  Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes , 1996, The Journal of cell biology.

[37]  T. Reiman,et al.  Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma , 2005, Modern Pathology.

[38]  A. Marchetti,et al.  Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. , 2009, The American journal of pathology.

[39]  W. Hohenberger,et al.  Cdc2 as prognostic marker in stage UICC II colon carcinomas. , 2009, European journal of cancer.

[40]  Y. Miyoshi,et al.  Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  M. Chatfield,et al.  Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  F. Lallemand,et al.  Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy , 2011, Molecular Cancer.

[43]  K. Klinger,et al.  Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence. , 2010, Experimental cell research.

[44]  Phang-lang Chen,et al.  Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. , 2008, Cancer research.

[45]  E. Sakamoto-Hojo,et al.  In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. , 2012, Journal of drugs in dermatology : JDD.

[46]  Janette Vardy,et al.  The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. , 2012, Critical reviews in oncology/hematology.

[47]  M. Izquierdo,et al.  RNA interference against Hec1 inhibits tumor growth in vivo , 2006, Gene Therapy.

[48]  D. Scudiero,et al.  Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells , 2007, Gene Therapy.

[49]  J. Russo,et al.  Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells. , 1998, Anticancer research.